Multiple Myeloma Clinical Trials

527 recruitingLast updated: June 6, 2026

There are 527 actively recruiting multiple myeloma clinical trials across 55 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include New York, New York, United States, Boston, Massachusetts, United States, Atlanta, Georgia, United States. Updated daily from ClinicalTrials.gov.


Multiple Myeloma Trials at a Glance

527 actively recruiting trials for multiple myeloma are listed on ClinicalTrialsFinder across 6 cities in 55 countries. The largest study group is Phase 2 with 199 trials, with the heaviest enrollment activity in New York, Boston, and Atlanta. Lead sponsors running multiple myeloma studies include Institute of Hematology & Blood Diseases Hospital, China, Memorial Sloan Kettering Cancer Center, and Janssen Research & Development, LLC.

Browse multiple myeloma trials by phase

Treatments under study

About Multiple Myeloma Clinical Trials

Looking for clinical trials for Multiple Myeloma? There are currently 383 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Multiple Myeloma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Multiple Myeloma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 527 trials

Recruiting
Phase 2

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

Multiple Myeloma
Janssen Research & Development, LLC60 enrolled17 locationsNCT07149857
Recruiting

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

Non-small Cell Lung CancerMultiple MyelomaLymphoma, Non-Hodgkin+2 more
National Cancer Institute (NCI)500 enrolled1 locationNCT02682667
Recruiting
Phase 3

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Multiple Myeloma
Pfizer492 enrolled271 locationsNCT06152575
Recruiting
Phase 2

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

Multiple Myeloma
Janssen Research & Development, LLC210 enrolled38 locationsNCT06500884
Recruiting

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma
Janssen Pharmaceutica N.V., Belgium300 enrolled89 locationsNCT05160584
Recruiting
Phase 4

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Multiple Myeloma
Janssen Research & Development, LLC295 enrolled50 locationsNCT05201781
Recruiting
Phase 3

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma
Janssen Research & Development, LLC700 enrolled8 locationsNCT07518186
Recruiting
Phase 3

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Multiple Myeloma
Janssen Research & Development, LLC795 enrolled242 locationsNCT06208150
Recruiting
Phase 2

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma
Janssen Research & Development, LLC157 enrolled51 locationsNCT07266441
Recruiting

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

Relapsed Refractory Multiple Myeloma (RRMM)
Janssen-Cilag Ltd.900 enrolled68 locationsNCT06285318
Recruiting
Phase 1

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC180 enrolled29 locationsNCT05652335
Recruiting
Phase 3

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Multiple Myeloma
Janssen Research & Development, LLC1,590 enrolled270 locationsNCT05552222
Recruiting
Phase 3

A Study of Daratumumab

Multiple Myeloma
Janssen Research & Development, LLC500 enrolled92 locationsNCT05438043
Recruiting
Phase 2

Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant

Multiple MyelomaPlasma Cell Leukemia
University of Utah120 enrolled1 locationNCT05405387
Recruiting
Phase 3

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma
Janssen Research & Development, LLC400 enrolled65 locationsNCT07258511
Recruiting
Phase 4

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Multiple Myeloma
Pfizer80 enrolled28 locationsNCT06057402
Recruiting
Phase 4

A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma
Johnson & Johnson Private Limited75 enrolled12 locationsNCT07030517
Recruiting
Phase 2

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)
Regeneron Pharmaceuticals116 enrolled39 locationsNCT06140524
Recruiting
Phase 1

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma
AbbVie210 enrolled45 locationsNCT05650632
Recruiting
Phase 1

A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

Multiple MyelomaHematologic Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.33 enrolled1 locationNCT07255898